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Abstract
Background: To minimize potential risk of intussusception, the World Health Organization (WHO) recommended in 2009
that rotavirus immunization should be initiated by age 15 weeks and completed before 32 weeks. These restrictions could
adversely impact vaccination coverage and thereby its health impact, particularly in developing countries where delays in
vaccination often occur.
Methods and Findings: We conducted a modeling study to estimate the number of rotavirus deaths prevented and the
number of intussusception deaths caused by vaccination when administered on the restricted schedule versus an
unrestricted schedule whereby rotavirus vaccine would be administered with DTP vaccine up to age 3 years. Countries were
grouped on the basis of child mortality rates, using WHO data. Inputs were estimates of WHO rotavirus mortality by week of
age from a recent study, intussusception mortality based on a literature review, predicted vaccination rates by week of age
from USAID Demographic and Health Surveys, the United Nations Children’s Fund (UNICEF) Multiple Indicator Cluster
Surveys (MICS), and WHO-UNICEF 2010 country-specific coverage estimates, and published estimates of vaccine efficacy and
vaccine-associated intussusception risk. On the basis of the error estimates and distributions for model inputs, we
conducted 2,000 simulations to obtain median estimates of deaths averted and caused as well as the uncertainty ranges,
defined as the 5th–95th percentile, to provide an indication of the uncertainty in the estimates. We estimated that in low
and low-middle income countries a restricted schedule would prevent 155,800 rotavirus deaths (5th–95th centiles, 83,300–
217,700) while causing potentially 253 intussusception deaths (76–689). In contrast, vaccination without age restrictions
would prevent 203,000 rotavirus deaths (102,000–281,500) while potentially causing 547 intussusception deaths (237–
1,160). Thus, removing the age restrictions would avert an additional 47,200 rotavirus deaths (18,700–63,700) and cause an
additional 294 (161–471) intussusception deaths, for an incremental benefit-risk ratio of 154 deaths averted for every death
caused by vaccine. These extra deaths prevented under an unrestricted schedule reflect vaccination of an additional 21%–
25% children, beyond the 63%–73% of the children who would be vaccinated under the restricted schedule. Importantly,
these estimates err on the side of safety in that they assume high vaccine-associated risk of intussusception and do not
account for potential herd immunity or non-fatal outcomes.
Conclusions: Our analysis suggests that in low- and middle-income countries the additional lives saved by removing age
restrictions for rotavirus vaccination would far outnumber the potential excess vaccine-associated intussusception deaths.
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Introduction
Rotavirus infection is the leading cause of fatal diarrhea among
children younger than 5 y, accounting for 453,000 deaths in the
year 2008 based on recently published World Health Organiza-
tion (WHO) estimates [1]. To curb this large toll of severe
rotavirus disease, in 2006, the WHO recommended two rotavirus
vaccines—Rotarix (GSK Biologicals) and RotaTeq (Merck &
Co.)—for use in Europe and the Americas, and in 2009, they
expanded this recommendation to all children worldwide [2].
These recommendations reflected the growing availability of
evidence of the good efficacy profile of rotavirus vaccines—first
from clinical trials in high- and middle-income countries in the
Americas and Europe in 2006 and then also from low-income
settings in Africa and Asia in 2009 [3–6].
Because a previous rotavirus vaccine (RotaShield) was found to
be associated with intussusception, a rare form of bowel
obstruction [7], the pivotal pre-licensure trials in the Americas
and Europe for both currently available rotavirus vaccines were
conducted in over 60,000 infants each to exclude this risk; these
trials did not show an increase in risk of vaccine-associated
intussusception similar to that found with Rotashield [3,4].
However, recent data on the postlicensure safety of rotavirus
vaccines generated from these countries has suggested a possible
low level risk of intussusception (,one to two excess cases per
100,000 vaccinated infants) in some countries but not in others
[8,9]. On the basis of considerations that this low level risk is
greatly exceeded by the observed health benefits of vaccination,
national and international policy and regulatory bodies have
continued to support recommendations for use of rotavirus vaccine
[8,9].
In 2009, WHO recommended that rotavirus vaccines should
not be initiated for infants aged 15 wk or older, with all doses
being completed by 32 wk [2]. These age restrictions were driven
by concerns about intussusception risk. Natural intussusception
rarely occurs before 3 mo of age and the incidence increases 10-
fold between 3 and 6 mo of age [10]. Therefore, a constant
vaccine-associated relative risk (RR) of intussusception, particu-
larly with the first vaccine dose that has been primarily associated
with risk, would translate to more excess cases if infants were
vaccinated late, beyond 3 mo of age. Similar findings were
observed in the United States after use of RotaShield, prompting a
debate about whether restriction of RotaShield to infants younger
than 3 mo of age would have averted withdrawal of the vaccine
[10–12]. A consequence of these strict age restrictions in countries
with vaccination delays is that those arriving late for immunization
would potentially not have access to the benefits of rotavirus
vaccination [13,14].
To facilitate decision making, we previously undertook a
scenario analysis assessing the benefits and risks of a rotavirus
vaccination strategy with and without an age restriction [15].
Since this analysis, new evidence has been published on several key
parameters for the scenario analysis, including data on efficacy of
rotavirus vaccines in Africa and Asia [5,6], the effect of rotavirus
vaccines on diarrhea deaths [16,17], postlicensure data on risk of
intussusception with current rotavirus vaccines [8,9,18], the
release of updated estimates of rotavirus mortality by WHO [1]
and age distribution of rotavirus disease by week of age [19], and
updated data on timeliness of vaccination coverage in low- and
middle-income countries [20]. The availability of these new data
and the imminent introduction of rotavirus vaccines in many
developing countries in Africa during the next 2 y prompted us to
revise our previous analysis to provide policy makers with the most
up-to-date evidence to inform decisions of best approaches to
global implementation of rotavirus vaccines.
Methods
We focused this analysis exclusively on the benefits of rotavirus
mortality reduction and potential risk of fatal intussusception in
children ,5 y of age in 158 low- and middle-income countries
with a birth cohort of 123.6 million where 99.9% of the global
rotavirus mortality occurs. To explore the effect of age restriction
in different parts of the world, we grouped these countries on the
basis of child mortality rates, according to WHO mortality strata
[21], and assigned to one of four groups: group B and C (countries
with low child mortality), group D-Americas (countries in the
Americas with high child mortality), group D-Asia (countries in
Asia with high child mortality), and group D & E-Africa (countries
in Africa with high child mortality). Because group A countries
with very low child mortality (i.e., high-income) represent ,0.1%
of the global rotavirus deaths, they were excluded from this
analysis.
Vaccination Strategies and Coverage Estimates
For both immunization strategies, restricted and unrestricted,
we assumed that rotavirus vaccine would be given at the same time
as the diphtheria-tetanus-pertussis (DTP) vaccine and that vaccine
coverage in the individual countries would be equal to the
proportion of infants receiving each of the three DTP doses by
week of age (i.e., proportion vaccinated, rv) during the first 3 y of
life. Under the restricted schedule, if infants received their first
DTP dose by #14 wk of age, we assumed they would receive all
doses up to 32 wk of age, but if they first appeared after 14 wk,
they would remain unvaccinated. On the unrestricted schedule,
vaccine would be administered according to the age-specific
coverage rates for each of the DTP dose up to 3 y of age.
Our DTP coverage estimates are based on vaccination data
from household USAID Demographic and Health Surveys (DHSs)
[22] and the United Nations Children’s Fund (UNICEF) Multiple
Indicator Cluster Surveys (MICS) [23] that were administered in
48 countries between 1996 and 2009. To estimate coverage for
countries without DHS or MICS data, overall WHO-UNICEF
2010 country-specific coverage estimates were converted into age-
specific coverage rates using regression coefficients to predict
lognormal curves of timeliness. These were derived from the
available DHS/MICS survey data and extrapolated to countries
without a survey within a WHO region and mortality stratum.
Timeliness was determined by WHO sub-region and adjusted for
trends between the DHS/MICS survey year and 2010 using the
WHO-UNICEF 2010 best estimates for DTP coverage data,
drop-out rate between DTP1 and DTP3, the target age
recommended in the country schedule, and the gross domestic
product per capita [24]. This process was done separately for
DTP1 and DTP3. DTP2 timeliness assumed the average of the
regression coefficients used for DTP1 and DTP3.
Our analysis does not allow catch-up immunization and
assumes no improvement in timeliness with the introduction of
rotavirus vaccine.
Assessment of Benefits—Base Scenario
Estimated numbers of country-specific rotavirus deaths (lrv)
were obtained from WHO, using the 95% CIs to define the
triangular distributions around the point estimate (Table 1) [1].
On the basis of a WHO-sponsored review of published and
unpublished studies on age distribution of diarrhea mortality and
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rotavirus-associated hospitalizations by week of age, we predicted
1-wk gamma age distributions for the first year of life and 4-wk age
categories thereafter for countries in different WHO regions [19].
Rotavirus vaccine efficacy (erv) against fatal rotavirus disease was
estimated from clinical trials or vaccine effectiveness studies in
each WHO region (Tables 1–2) [3,5,6,25–29]. Because efficacy
against rotavirus mortality could not be directly measured in the
trials, we applied efficacy estimates against the most severe
rotavirus disease outcome reported in the study [3,5,6,25–29].
This approach was reasonable given that three nationwide studies
from Latin America have documented reductions in diarrhea
deaths after vaccine introduction that has approximated reduc-
tions based on the efficacy of these vaccines against severe
rotavirus disease [16,17,30]. Because both rotavirus vaccines have
performed similarly in clinical trials, we assumed the same overall
efficacy for the two-dose Rotarix and the three-dose RotaTeq
vaccine. The efficacy parameters were age-stratified (,1 y and
.1 y of age) because studies have documented lower efficacy
among children older than 1 y of age [5,25,27]. Efficacy of partial
vaccination (first dose) was also available from one country in the
B & C region [27], and one country in the D-Americas region
[25], but not for D-Asia and D & E-Africa. We therefore reduced
the point estimates for full vaccine efficacy for Asia and Africa by
the same proportion as the relative difference in efficacy between
the full and partial series in D: Americas region. We used 95% CIs
from the respective studies to define the beta distribution around
the vaccine efficacy point estimates.
The number of rotavirus deaths prevented was obtained from
lrvervrv, where lrv is the number of rotavirus deaths by week of age, erv is
the vaccine efficacy, and rv is the proportion vaccinated by week of age.
Assessment of Risk—Base Scenario
Risk of intussusception has been documented after postlicensure
use of Rotarix and RotaTeq in four different studies [8,9,31,32].
Each of these studies identified an approximate 4- to 6-fold
increase in risk relative to background during the first week after
dose 1 (Table 3), a magnitude of risk that would not have been
detected in the clinical trials. No effect modification of risk with
age at vaccination was reported in these studies, but the first dose
of vaccine was largely administered before 15 wk. In two
Table 1. Estimates of rotavirus mortality and intussusception incidence by WHO mortality group.
Mortality, Incidence, and Fatality WHO Mortality Group Estimate (Lower Bound, Upper Bound)
B & C D: Americas D: Asia D & E: Africa
Rotavirus mortality 26,700 (24,000–29,000) 5,300 (4,600–5,900) 188,300 (160,000–217,000) 232,500 (198,000–268,000)
Intussusception incidence (range) 53.3 (17.7–88.2) 53.3 (17.7–88.2) 53.3 (17.7–88.2) 53.3 (17.7–88.2)
Intussusception case fatality 5% (4–6) 10% (8–12) 25% (20–30) 25% (20–30)
doi:10.1371/journal.pmed.1001330.t001
Table 2. Estimates of efficacy for partial and full series of rotavirus vaccine against the most severe reported outcome of rotavirus
gastroenteritis, by WHO mortality group.
WHO Mortality Group Reference Location Outcome Vaccine Efficacy
a
,1 y of Age 1 y of Age
Percent (95% CI) Percent (95% CI)
Full series efficacy during
first year of life
B & Cb [26] Latin America $19 97 84–100 97 84–100
D: Americasb [25] Nicaragua $15 77 39–92 77 39–92
D: Asia/D & E Africa [5,6,29] Bangladesh, Vietnam,
Ghana, Kenya, Mali
$15 67 37–84 34 216 to 63
D & E Africac [28]b South Africa & Malawi $11 61 44–73 — —
Partial series efficacy
B & C [27] El Salvador Hospitalizations 51 26–67 51 26–67
D: Americas [25] Nicaragua Hospitalizations 55 22–74 55 22–74
D: Asia/D & E Africad — — — 48 30–68 24 0–51
aBecause vaccine efficacy against rotavirus deaths was not available, the model input was efficacy against the most severe reported form of rotavirus gastroenteritis in
the clinical trial ($11 denotes ‘‘severe’’ diarrhea and $15 denotes ‘‘very severe’’ diarrhea on 20 point Vesikari clinical scoring system).
bNo decline in efficacy by age was reported by age for the very severe outcome, thus the efficacy estimate for children ,2 were applied to both age groups,1 and 1 y
of age.
cThis trial measured efficacy during the first year of life. No estimates of efficacy were available against very severe disease that would serve as a better proxy for death
(i.e., Vesikari $15) at these sites in Malawi and South Africa. Consistent with all other rotavirus efficacy trials where positive correlation exists between efficacy and
severity score, it was assumed that efficacy in South Africa and Malawi would be higher against Vesikari score $15 than Vesikari $11. For the model, estimates of
efficacy against ‘‘very severe’’ rotavirus diarrhea were from sites in Africa and Asia where these data were available [5,6,29].
dBecause no partial vaccine efficacy estimates were available for Africa and Asia, we assumed that a proportional difference in efficacy between full and partial
vaccination that was observed in high mortality country of Nicaragua [25].
doi:10.1371/journal.pmed.1001330.t002
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additional countries, no risk of intussusception was identified after
the first vaccine dose [9,18]. Risk of intussusception was not
identified after the first dose in Brazil (RR=1.1; 95% CI= 0.3–
3.3) or the United States (RR=1.2; 95% CI=0.03–6.8). However
in view of the wide CIs, particularly in the United States, a risk of
small magnitude similar to that detected in the other four studies
cannot be excluded [9,18]. In Brazil, a statistically significant 2-
fold risk was also identified in the first week after dose 2.
We obtained dose-specific pooled estimates of RR from each of
the regions where some increase in RR of intussusception was
identified (Table 3). To err on the side of risk, we excluded the US
safety data from the pooled analysis because no risk was identified.
For pooled estimates of vaccine-associated intussusception risk, we
used the weighted average of the logarithm of the RR,
glog(RRi)vi/gvi, where weight (vi) for each study [8,9,31,32] is
the inverse of the variance computed from the reported 95% CIs
[33]. The variance of the weighted average log RR is the inverse of
the sum of the each weight (1/gvi) and was used to compute the
95% CIs for the pooled risk estimate. For the uncertainty analyses,
we used the 95% CIs to define the gamma distribution around the
RR estimates.
The average annual incidence of natural intussusception by week
of age ((lis) was estimated from published studies. Because natural
intussusception is a very rare disease, we restricted our review to
studies reporting either national incidence of intussusception or
incidence of intussusception from a minimum of five hospitals with
known catchment population, stratified by age [34–51]. While
intussusception incidence in this review ranged from 18–88 per
100,000 infants, the age distribution of intussusception was similar
between the different studies. Thus, to obtain intussusception
incidence by week of age (lis), we applied the global intussusception
incidence among infants and fit a gamma curve to intussusception
surveillance data from the United States [45], the only country
where intussusception incidence was available by week of age. For
uncertainty analysis, parameters of the gamma curve for lis were
sampled from a normal distribution, assuming standard deviation is
equal to 5% of the mid-parameter values.
Death caused by intussusception is uncommon in industrialized
countries, occurring in ,1% of the cases [52]. In a recently
conducted national study from 16 hospitals in Mexico and 43
hospitals in Brazil (WHO group B & C), case fatality for
intussusception was 1% and 5%, respectively [9]. One large study
from nine countries across Africa indicated an average case fatality
of about 12% [53]. No reliable estimates of case fatality were
available for countries in D-Americas and D-Asia. Thus, we
conservatively estimated the case fatality (dis) to be 5% for B & C
countries, 10% for D-Americas, 25% for D-Asia, and 25% for D &
E-Africa. We sampled from a beta distribution, assuming standard
deviation is equal to 5% of the mid parameter values to specify the
upper and lower limits of dis in uncertainty analyses.
The number of intussusception deaths associated with vaccination,
during the first week after dose 1 and 2, was obtained fromBrv[(lisRRi)
2 lis]dis, where B is the number of births, rv is the proportion
vaccinated by week of age, lis is the intussusception incidence by week
of age, RRi is the RR during the week after each dose, and dis the
proportion of intussusception events that lead to death.
Sensitivity Analysis
We conducted a one-way sensitivity analysis to determine the
impact on the benefit-risk ratios when assuming four conservative
scenarios that would favor risk and one that would favor vaccine:
(1) We assumed a relative increase of 20% in incidence and case
fatality of intussusception. (2) We explored the impact of effect
modification of risk by age at vaccination, by doubling estimates of
RR of intussusception when dose 1 of rotavirus vaccine was
administered to infants older than 14 wk of age. (3) We assumed a
scenario of low vaccine efficacy by inputting the lower confidence
limit for each of the efficacy estimates. (4) We explored the effect of
a ‘‘pessimistic’’ situation combining all of the preceding three
scenarios. (5) We also assessed the effect of an ‘‘optimistic’’
scenario of high vaccine efficacy related to factors such as possible
indirect benefits or higher efficacy among children vaccinated at
older ages with lesser interference of vaccine take from circulating
transplacental antibodies.
Uncertainty Analysis
The above analyses yielded estimates of rotavirus deaths averted and
intussusception deaths caused under age-restricted and -unrestricted
Table 3. Pooled estimates of risk after doses 1 and 2 of rotavirus vaccine.
Country Reference Rotavirus Vaccine RR Lower 95% Limit
Upper 95%
Limit
Dose 1
Australia [8] Pentavalent 3.9 1.5 9.9
Australia [8] Monovalent 4.1 1.3 13.5
Mexico [9] Monovalent 5.3 3 9.3
Mexico [31] Monovalent 6.5 4.2 10.1
Global reporting [32] Monovalent 5.0 1.7 14.3
Pooled estimatea 5.5 4.1 7.5
Dose 2
Mexico [9] Monovalent 1.8 0.9 3.8
Mexico [31] Monovalent 1.3 0.8 2.1
Brazil [9] Monovalent 2.6 1.3 5.2
Pooled estimatea 1.7 1.2 2.4
aWe used the weighted average of the logarithm of the RR, glog(RRi)vi/gvi, where weight (vi) for each study is the inverse of the variance computed from the
reported 95% CIs [33]. The variance of the weighted average log RR is the inverse of the sum of each weight (1/gvi) and was used to compute the 95% CIs for the
pooled risk estimate.
doi:10.1371/journal.pmed.1001330.t003
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vaccination strategies. We conducted a probabilistic uncertainty
analysis to assess the potential impact of simultaneous variation
of each of the model inputs (lrv, erv, rv, lis, RR) on the
precision of the benefit-risk estimates. We shifted the lognormal
timeliness curves and gamma rotavirus and intussusception age
curves by simultaneously sampling new shape, shift, and scale
parameters for each run, with each parameter being sampled
from a normal distribution with standard deviation equal to 5%
of the original parameter value. On the basis of the error
estimates and error distributions described for each of the model
inputs, we conducted 2,000 simulations to obtain the median
estimates of deaths averted and caused as well as the
uncertainty ranges, defined as the 5th–95th percentile, to
provide an indication of the uncertainty in the estimates. All
analyses were done with Microsoft EXCEL (Microsoft Corp,
2007).
Results
Approximately 453,000 rotavirus-associated deaths are estimat-
ed among children younger than 5 y annually without a rotavirus
vaccination program (Figure 1). We project that a rotavirus
vaccination program under the current age-restricted schedule
would prevent almost 33% or 155,800 of these deaths (5th–95th
centiles, 83,300–217,700) if delivered at the same ages at which the
DTP vaccine is currently being delivered in these countries
(Table 4). Without the age restrictions, a program would prevent
45% or 203,000 deaths of all rotavirus deaths (102,000–281,500),
which would represent 47,200 more deaths prevented (18,700–
63,700) than with an age-restricted schedule. These additional
deaths prevented under an unrestricted vaccination schedule
reflect an additional 18%, 21%, 25%, and 22% of the children
receiving DTP1 in the WHO B & C, D-Americas, D-Asia, and D-
Africa countries, respectively, compared to the age-restricted
schedule in these countries (Figure 2).
From the perspective of risk, a rotavirus vaccination program
limiting vaccination to children ,15 wk of age would cause about
253 intussusception deaths (76–689) (Table 4). In contrast, a
program without age restrictions would cause nearly 547
intussusception deaths (237–1,160). Thus, a vaccination policy
without any age restrictions for use of rotavirus vaccines in low-
and middle-income WHO countries would avert an additional
47,200 rotavirus-associated deaths and cause an additional 294
intussusception-associated deaths, compared to the current age-
restricted strategy (Table 5). The median incremental benefit-risk
ratio in all mortality strata was nearly 154 deaths averted for every
death caused, ranging from 55–318 deaths averted for every death
caused across the different mortality strata (Figures 3 and 4).
Under the scenarios of effect modification of risk with age at
vaccination and increased incidence and case fatality of intussus-
ception, an unrestricted schedule would cause 603 (174–946) and
423 (232–678) excess deaths, respectively, while averting about
47,200 rotavirus deaths (18,700–63,700) (Table 5). A scenario
where efficacy approximated the lower confidence limit in the
clinical trials would avert an additional 20,400 rotavirus deaths
(8,500–34,300) under an unrestricted schedule. With pessimistic
assumptions of high intussusception incidence and case fatality,
high risk, and low efficacy, a vaccination program without age
restrictions would cause 868 intussusception deaths (506–1,362)
while preventing 20,400 rotavirus deaths (8,500–34,300), for a
Figure 1. Age distribution of rotavirus deaths among children under 5 y, by WHO mortality group.
doi:10.1371/journal.pmed.1001330.g001
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benefit-risk ratio of 24. In contrast, the benefit-risk ratio would
approximate 220 (116–407) under an optimistic scenario of high
vaccine efficacy.
Discussion
Our analysis demonstrates that if first dose of rotavirus vaccine
is restricted to children 14 wk of age or younger, rotavirus vaccines
would prevent about 155,800 of the 453,000 rotavirus deaths
occurring in children ,5 y of age annually worldwide while
resulting in 253 intussusception deaths. While most of the gap in
preventable rotavirus deaths is due to the moderate efficacy of the
vaccines in high mortality settings, the current age restrictions on
rotavirus vaccination also contribute by potentially excluding
nearly 21%–25% of the world’s children, those with the highest
risk of rotavirus mortality, from receiving these vaccines. Lifting
the age restriction for the first dose of rotavirus vaccination would
save an additional 47,200 lives yearly and would result in an
additional 294 intussusception deaths, for an incremental benefit
of saving 154 lives for each excess intussusception death caused.
In the past 5 y, with the introduction of rotavirus vaccines in
nearly 30 countries worldwide, substantial experience has been
gained with regard to the safety and effectiveness of these vaccines
in the real-world setting, including against deaths [8,9,16–
18,25,27,54,55]. Moreover, clinical trials for these vaccines have
documented their efficacy in target populations of Asia and Africa,
where majority of the rotavirus deaths occur. Given these
encouraging data, the ability of the vaccines to reach children
with the highest mortality will be a major determinant of their life-
saving impact.
Our base estimates are conservative, erring on the side of
overestimating vaccine risk for four reasons. First, over 45
publications have documented remarkable declines in severe
diarrhea and rotavirus disease, including deaths, since their
introduction in national immunization programs worldwide
[55]. Many of these studies from different locations have
demonstrated significant declines in unvaccinated members of
the community, indicating indirect benefits of vaccination that
we did not account for in our analysis [56–59]. Second, because
of interference from circulating transplacental antibodies during
the first several months of life, immune response to vaccine and
thus efficacy is likely to be higher when children are vaccinated
at older ages. For example, anti-rotavirus IgA geometric mean
titers for Vietnamese infants vaccinated against rotavirus at 9
and 13 wk were lower (77 U/ml) compared to infants vacci-
nated at 9 and 17 wk of life (176 U/ml) [60]. Third, we
assumed that some risk of intussusception exists following each
of the first two doses of rotavirus vaccine in all countries
worldwide; however, risk of intussusception has varied by
setting, and robust studies in two large countries have not
identified risk after dose 1 [9,18]. Fourth, even in our base
scenario, we assumed high rates of intussusception case fatality
in all WHO regions, about 2-fold higher than those reported in
the literature.
Table 4. Rotavirus deaths averted versus excess intussusception deaths caused under age-restricted and age-unrestricted
rotavirus vaccination strategies, by WHO mortality group and age.
Vaccination Strategy Rotavirus Deaths Averted (95% CI)
a Intussusception Deaths Causeda (95% CI)
Benefit to
Risk Ratio
Age Restrictionb
No Age
Restriction Excess Age Restrictionb
No Age
Restriction Excess
B & C countries
Median 18,200 22,700 4,500 35 53 18 247
5th percentile 15,500 19,700 4,200 10 19 9 138
95th percentile 20,500 25,200 4,700 94 127 33 519
D: Americas
Median 2,600 3,300 700 3 5 2 343
5th percentile 1,400 1,800 400 1 2 1 152
95th percentile 3,200 4,000 800 9 12 3 674
D: Asia
Median 55,400 76,800 21,400 118 275 157 133
5th percentile 25,200 32,200 7,000 36 120 84 43
95th percentile 83,400 115,300 31,900 317 576 259 286
D: Africa
Median 79,600 100,200 20,600 96 212 116 167
5th percentile 40,300 46,900 6,600 28 96 68 50
95th percentile 111,100 138,300 27,200 265 441 176 328
All strata
Median 155,800 203,000 47,200 253 547 294 154
5th percentile 83,300 102,000 18,700 76 237 161 55
95th percentile 217,700 281,500 63,700 689 1,160 471 318
aEstimates of rotavirus deaths averted and intussusception deaths caused are based on efficacy, risk, and case-fatality parameters in Tables 1–3. Vaccination coverage is
based on DTP vaccination rates from household DHSs and UNICEF MICSs.
bAge restriction denotes dose 1 administration by 15 wk and the full series by 32 wk of age.
doi:10.1371/journal.pmed.1001330.t004
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On the other hand, the benefit-risk ratios might be inflated due
to several factors. First, our base scenario assumes that the risk of
intussusception relative to background does not increase with age.
After the withdrawal of RotaShield, a debate persisted with regard
to whether the RR of intussusception might have been higher for
infants vaccinated beyond 14 wk of age [11,12]. While limited
data from an evaluation in Mexico does not suggest effect
modification of risk by age for current vaccines [9], we
incorporated a scenario of increased risk with age at vaccination
that indicated that vaccination would avert 75 rotavirus deaths for
each excess intussusception death. Second, our model might have
overestimated vaccine coverage among children at the highest risk
of dying from rotavirus as these might be the hardest to reach, thus
inflating the mortality benefits of vaccination relative to the risks in
our model. However, data from Mexico and Brazil, where
substantial reductions in diarrhea deaths have occurred in all
regions of both countries after the introduction of vaccine [16,17],
provides some reassurance that vaccine is reaching those at the
highest risk of dying.
While the numerical benefits of relaxing the age restriction on
rotavirus vaccination exceed the risks, other factors are relevant for
policy considerations. First, the age restrictions for rotavirus
vaccines potentially offer an incentive to improve timeliness of
vaccination, which would potentially have far reaching benefits
beyond just prevention of rotavirus disease. However, reasons for
delays in vaccination in developing countries are complex and it is
not known if a policy of restricting the first dose of rotavirus
vaccines alone would be a sufficient motivational factor for parents
and countries to improve timeliness of vaccination. Indeed, some
delays may be due to unavoidable factors, such as contraindica-
tions. Second, while the unrestricted vaccination scenario allows
for vaccination at any age during the first 3 y of life, few children
arrive for vaccination beyond 1 y of life. It is important to note
that delays in vaccination particularly beyond 1 y of life will
reduce benefits substantially because of increasing probability of
acquiring natural immunity from wild-type rotavirus infection.
Third, a death caused by an intervention may be perceived worse
than a death caused by a failure to intervene [61–63]. However,
some evidence suggests that individuals may regret disease
resulting from withholding vaccine as much as side effects from
vaccination [63]. Furthermore, after the RotaShield experience,
ethicists argued equal culpability for deaths caused by withholding
the vaccine as for deaths resulting from the vaccine [64]. Finally,
our analysis did not address high income countries where mortality
from both rotavirus disease and from intussusception is uncom-
mon, and thus the benefit-risk considerations will differ. Further-
more, vaccination is more timely in these settings (e.g., in the
United States, 93% of the DTP1 is given by 15 wk of age [65]),
and thus decisions will likely have to be made at a country level
based on evaluation of local data.
In summary, using emerging, real-world data on rotavirus and
intussusception mortality and rotavirus vaccine efficacy, safety,
Figure 2. Vaccine coverage for dose 1 of DTP by week of age and WHO mortality group based on the DHSs and UNICEF MICs.
doi:10.1371/journal.pmed.1001330.g002
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Table 5. Additional lives saved versus deaths caused by loosening the age restrictions for rotavirus vaccines in WHO high and very
high mortality group.
Scenario Median (5th Percentile, 95th Percentile)
Lives Saved Deaths Caused Benefit/Risk Ratio
Basea 47,200 (18,700–63,700) 294 (161–471) 154 (55–318)
Base+higher intussusception rate and case fatalityb 47,200 (18,700–63,700) 423 (232–678) 107 (38–221)
Base+increase RR with age at dose 1c 47,200 (18,700–63,700) 603 (174–946) 75 (27–143)
Base with low vaccine efficacy 20,400 (8,500–4,300) 294 (161–471) 71 (24–159)
Pessimisticd 14,400 (7,400–28,300) 703 (459–1,042) 24 (9–51)
Optimistic (Base+high vaccine efficacy)e 65,800 (39,900–77,000) 294 (161–471) 220 (116–407)
aAssumes point estimates for vaccine efficacy and intussusception risk and case-fatality estimates presented in Tables 1–3.
bAssumes 20% relative increase in incidence and case fatality of intussusception compared to base scenario.
cAssumes a doubling of RR of vaccine associated risk of intussusception among children receiving dose 1 beyond 15 wk of age.
dPessimistic scenario assumes base scenario with: (1) 20% increase in background incidence and case fatality of intussusception compared to base scenario; (2) doubling
of relative among children vaccinated with dose 1 beyond 15 wk of age; and (3) lower 95% confidence limit for vaccine efficacy.
eOptimistic scenario assumes the upper confidence limit for vaccine efficacy in each setting.
doi:10.1371/journal.pmed.1001330.t005
Figure 3. Global analysis of the relationship between esimated number of rotavirus gastroenteritis deaths avoided versus
intussusception deaths caused by removal of the age restrictions for rotavirus vaccination. These estimates are from 2,000 simulations
with each blue dot representing a potential estimate of rotavirus deaths prevented (y-axis) versus intussusception deaths caused (x-axis) from
removal of the age restrictions given the uncertainty on the parameters in the model: rotavirus mortality, vaccine efficacy, vaccine coverage,
intussusception incidence, intussusception risk from vaccine, and intussusception fatality. The black square represents the median estimate.
doi:10.1371/journal.pmed.1001330.g003
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and coverage, we estimate that removing the age restrictions on
rotavirus vaccination would avert 47,200 additional rotavirus
deaths in low- and middle-income countries. In April 2012,
WHO’s Strategic Advisory Group of Experts reviewed the
evidence presented in this paper and recognized that the 15-wk
and 32-wk age restrictions for rotavirus vaccines are preventing
vaccination of many vulnerable children [66]. SAGE encourages
timely vaccination, but no longer universally recommends the age
restrictions, supporting their removal in seetings where mortality
benefits outweigh the risk so that many thousands more deaths
would be averted and immunization programs are able to
immunize children who are currently excluded from the benefits
of rotavirus vaccines. Age restriction policies will ultimately be
decided at country level, but this analysis has shown a clear case
for a change in policy that will be particularly instrumental for
saving lives in settings where mortality from rotavirus is high and
delays in timing of vaccination are common.
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Editors’ Summary
Background. Rotavirus causes severe diarrhea and vomit-
ing. It is responsible for a large number of hospitalizations
among young children in developed countries (an estimated
60,000 hospitalizations per year in the US in 2005, for
example). In poor countries, rotavirus is a major cause of
death in children under five. In 1998, the first rotavirus
vaccine, called RotaShield, was approved in the US by the
Food and Drug Administration. Shortly after the vaccine
became widely used, doctors noticed a small increase in a
problem called intussusception among the vaccinated
infants. Intussusception is a rare type of bowel obstruction
that occurs when the bowel telescopes in on itself. Prompt
treatment of intussusception normally leads to full recovery,
but some children with the condition need surgery, and
when the disease is left untreated it can be fatal. Because
intussusception is a serious condition and because very few
children die from rotavirus infection in the United States, the
US authorities stopped recommending vaccination with
RotaShield in 1999. The manufacturer withdrew the vaccine
from the market shortly thereafter.
Since then, two new vaccines (named Rotarix and RotaTeq)
have been developed. Before they were approved in the US
and elsewhere, they were extensively tested for any adverse
side effects, especially intussusception. No increase in the
risk for intussusception was found in these studies, and both
are now approved and recommended for vaccination of
infants around the world.
Why Was This Study Done? Since 2006, hundreds of
thousands of infants have been vaccinated with Rotarix or
RotaTeq, with safety being closely monitored. Some coun-
tries have reported a small increase in intussusception (one
to four additional cases per 100,000 vaccinated infants,
compared with one per 2,000 of cases that occur in
unvaccinated children). This increase is much lower than
the one seen previously with RotaShield. In response to
these findings, authorities in the US and other developed
countries as well as the World Health Organization declared
that the benefits of the vaccine outweigh the risks of the
small number of additional intussusception cases in both
developed and poor countries. However, because older
infants have a higher risk of naturally occurring intussuscep-
tion, they decided that the course of vaccination (three oral
doses for Rotarix and two for RotaTeq) should be initiated
before 15 weeks of age and completed before the age of 32
weeks. This is usually not a problem in countries with easy
access to health facilities. However, in many poor countries
where delays in infant vaccination are common, giving the
vaccine only to very young children means that many others
who could benefit from its protection will be excluded. In
this study, the researchers examined the risks and benefits of
rotavirus vaccination in poor countries where most of the
rotavirus deaths occur. Specifically, they looked at the
benefits and risks if the age restrictions were removed, with
a particular emphasis on allowing infants to initiate rotavirus
immunization even if they arrive after 15 weeks of age.
What Did the Researchers Do and Find? The researchers
used the most recent estimates for how well the vaccines
protect children in Africa and Asia from becoming infected
with rotavirus, how many deaths from rotavirus infection can
be avoided by vaccination, how many additional cases of
intussusception will likely occur in vaccinated children, and
what proportion of children would be excluded from
rotavirus vaccination because they are too old when they
come to a health facility for their infant vaccination. They
then estimated the number of rotavirus deaths prevented
and the number of intussusception deaths caused by
vaccination in two scenarios. The first one (the restricted
scenario) corresponds to previous guidelines from WHO and
others, in which rotavirus vaccination needs to be initiated
before 15 weeks and the full series completed before 32
weeks. The second one (called the unrestricted scenario)
allows rotavirus vaccination of children alongside current
routinely administered vaccines up to three years of age,
recognizing that most children receive their vaccination by 1
year of life.
The researchers estimated that removing the age restriction
would prevent an additional 154 rotavirus deaths for each
intussusception death caused by the vaccine. Under the
unrestricted scenario, roughly a third more children would
get vaccinated, which would prevent an additional approx-
imately 47,000 death from rotavirus while causing approx-
imately 300 additional intussusception deaths.
They also calculated some best- and worst-case scenarios.
The worst-case scenario assumed a much higher risk of
intussusception for children receiving their first dose after 15
weeks of life than what has been seen anywhere, and also
that an additional 20% of children with intussusception
would die from it than what was already assumed in their
routine scenario (again, a higher number than seen in
reality). In addition, it assumes a lower protection from
rotavirus death for the vaccine than has been observed in
children vaccinated so far. In this pessimistic case, the
number of rotavirus deaths prevented was 24 for each
intussusception death caused by the vaccine.
What Do These Findings Mean? If one accepts that
deaths caused by a vaccine are not fundamentally different
from deaths caused by a failure to vaccinate, then these
results show that the benefits of lifting the age restriction for
rotavirus vaccine clearly outweigh the risks, at least when
only examining mortality outcomes. The calculations are
valid only for low-income countries in Africa and Asia where
both vaccination delays and deaths from rotavirus are
common. The risk-benefit ratio will be different elsewhere.
There are also additional risks and benefits that are not
included in the study’s estimates. For example, early
vaccination might be seen as less of an urgent priority
when this vaccine can be had at a later date, leaving very
young children more vulnerable. On the other hand, when
many children in the community are vaccinated, even the
unvaccinated children are less likely to get infected (what is
known as ‘‘herd immunity’’), something that has not been
taken into account in the benefits here. The results of this
study (and its limitations) were reviewed in April 2012 by
WHO’s Strategic Advisory Group of Experts. The group then
recommended that, while early vaccination is still strongly
encouraged, the age restriction on rotavirus vaccination
should be removed in countries where delays in vaccination
and rotavirus mortality are common so that more vulnerable
children can be vaccinated and deaths from rotavirus
averted.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001330.
N The World Health Organization provides information on
rotavirus
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N Wikipedia has information on rotavirus vaccine and
intussusception (note that Wikipedia is a free online
encyclopedia that anyone can edit; available in several
languages)
N The US Centers for Disease Control and Prevention
rotavirus vaccination page includes a link to frequently
asked questions
N PATH Rotavirus Vaccine Access and Delivery has timely,
useful updates on status of rotavirus vaccines globally
Rotavirus Vaccine Benefit Risk
PLOS Medicine | www.plosmedicine.org 13 October 2012 | Volume 9 | Issue 10 | e1001330
